Pharmaceutical patents differ from software patents: pharma involves a few enormous single-molecule patents, so injunctions that operate like keeping trespassers off a skyscraper site are appropriate, while the assembly problem of many small overlapping patents calls for different rules.

normativepending

Speaker

Richard Epstein

Evidence Quote

“those things should be treated just like skyscrapers. Keep off unless you get my permission to come in.”

Source

Richard Epstein on Property Rights and Drug Patents 2/19/2007— EconTalk
Created: 10/30/2026, 3:22:16 PM

Your notes

Loading notes...